• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Team
  • News
EyeBio

EyeBio

  • Business Development
  • Contact

Back to Team

Kate Bingham, DBE

Managing Partner, SV Health Investors
EyeBio Board Chair

LinkedIn

As Managing Partner of SV Health Investors, Kate co-leads SV’s Biotech franchise, which has a long history of building high-value, successful new companies developing transformational medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company-creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas. Her investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.  

From May to December 2020 Kate served as Chair of the UK Vaccine Taskforce (VTF), which was set up in response to the COVID-19 pandemic to lead the UK’s efforts to discover and manufacture a COVID-19 vaccine. She was awarded a Dame Commander (DBE) rank in the Queen’s Birthday Honours in June 2021 for services relating to the procurement, manufacture, and distribution of COVID-19 vaccines.

Kate serves on the Board of the Francis Crick Institute and won the BioIndustry Association UK Lifetime Achievement Award in January 2017. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate has a first-class degree in Biochemistry from Oxford University and an M.B.A. from Harvard Business School, where she was a Baker Scholar.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Team
  • News
  • Business Development
  • Contact